Protection against oxidative damage caused by excessive reactive oxygen species (ROS) by an antioxidant network is essential for the health of tissues, especially in the cardiovascular system. Here, we identified a gene with important antioxidant features by analyzing a null allele of zebrafish ubiad1, called barolo (bar). bar mutants show specific cardiovascular failure due to oxidative stress and ROS-mediated cellular damage. Human UBIAD1 is a nonmitochondrial prenyltransferase that synthesizes CoQ10 in the Golgi membrane compartment. Loss of UBIAD1 reduces the cytosolic pool of the antioxidant CoQ10 and leads to ROS-mediated lipid peroxidation in vascular cells. Surprisingly, inhibition of eNOS prevents Ubiad1-dependent cardiovascular oxidative damage, suggesting a crucial role for this enzyme and nonmitochondrial CoQ10 in NO signaling. These findings identify UBIAD1 as a nonmitochondrial CoQ10-forming enzyme with specific cardiovascular protective function via the modulation of eNOS activity.
INTRODUCTION
Reactive oxygen species (ROS) play an important role in signal transduction and physiological regulation of the cardiovascular system by facilitating various biological responses, including senescence in heart and endothelial cells (ECs) (Lander et al., 1996; Finkel, 2003; Finkel and Holbrook, 2000; Hare and Stamler, 2005; D'Autré aux and Toledano, 2007) . In cardiovascular tissues, ROS are normally produced in response to RTK and GPC receptor signaling, as well as during mechanical (shear) stress. ROS help regulate cardiovascular homeostasis (Colavitti et al., 2002; Werner, 2004; Ushio-Fukai, 2006 ). An antioxidant network is required to balance these ROS and prevent oxidative damage, which may contribute to cardiovascular pathologies (Finkel, 2003; Giordano, 2005; Kuster et al., 2010) . Although several enzymes responsible for ROS production in ECs have been identified, many of the molecules involved in the endogenous antioxidant network are unknown.
A molecule known to play an important antioxidant role in the cardiovascular system is CoQ10 (also known as Coenzyme Q10 or ubiquinone) (Pepe et al., 2007; Kumar et al., 2009) . CoQ10 is the only endogenously synthesized lipid-soluble antioxidant (Crane, 2007; Bentinger et al., 2007) . It is available in the membranes of the Golgi, where it is present at an even higher concentration than in the mitochondria, as well as in plasma membranes (Kalen et al., 1987; Crane, 2001; Bentinger et al., 2008) . Although the biosynthesis of CoQ10 in mitochondria has been studied in detail, only a limited amount of data is available in regards to the synthesis of cellular membrane CoQ10. Several in vivo experiments suggest that CoQ10 synthesis may also occur in the Golgi and endoplasmic reticulum membranes, providing the cellular membrane CoQ10 pool (Kalé n et al., 1990) . However, although hypothesized, a ''nonmitochondrial'' CoQ10 biosynthetic enzyme has not been identified (Bentinger et al., 2010) . Identification of such an enzyme could be extremely useful in order to devise strategies to counteract the excess of ROS responsible for cellular oxidative damage (such as lipid peroxidation, protein nitrosylation, and DNA oxidation) and therefore balance redox signaling especially in cardiovascular tissues.
CoQ10 is a mobile lipophilic electron carrier that is critical for electron transfer both in the mitochondrial membrane for respiratory chain activity as well as in Golgi and plasma membranes for NAD(P)H-oxidoreductase-dependent reactions such as in NO synthesis (Navas et al., 2007) . Endothelial nitric oxide synthase (eNOS) is a critical regulator of cardiovascular functions by generating nitric oxide (NO), which is an important mediator of cardiovascular homeostasis (Alp and Channon, 2004; Fö rstermann and Sessa, 2012) . As in the case with nonmitochondrial CoQ10, eNOS is specifically localized in the Golgi and plasma membrane of heart and endothelial cells, and it can be differentially regulated in these two cellular compartments (Fulton et al., 2002) . Different reports have suggested that CoQ10 may improve endothelial dysfunction by ''recoupling'' eNOS and modulating NO-related signaling (Chew and Watts, 2004; Tsai et al., 2012) .
Here, we identify UBIAD1 as an enzyme for CoQ10 synthesis at the level of Golgi membranes and show that it is critical for oxidative stress protection. In particular, UBIAD1 protects cardiovascular tissues from eNOS-dependent oxidative stress. We propose a functional link between UBIAD1, CoQ10, and NO signaling during cardiovascular development and homeostasis.
RESULTS
Oxidative Stress and Cardiovascular Failure Characterize barolo Mutants By forward genetic screens for cardiovascular mutants (2005 Tuebingen screen; Jin et al., 2007) , we identified mutations in the barolo (bar) gene (bar t31131 and bar s847 ). These mutations are recessive and show complete penetrance and expressivity. bar mutants show distinct cranial vascular hemorrhages and pericardial edema in the context of wild-type body morphology ( Figure 1A) . To examine whether this phenotype is associated with cardiovascular defects, we crossed the mutations into Tg(kdrl:GFP) s843 ( Figure 1B ). The hemorrhagic phenotype in bar mutants is accompanied by endothelial regression and fragmentation in the cranial and trunk vascular compartments (Figures 1C and 1D) . Time-lapse analyses of trunk vasculature indicate that the bar phenotype starts around 36 hr postfertilization (hpf) (Movies S1, S2, S3, and S4) and that it is not due to general loss of blood flow. The cardiac edema of bar mutants is caused by a gradual breakdown of endocardial and myocardial cells in the heart, leading to the collapse of the heart between 60 and 72 hpf (data not shown). All these features lead to the complete cardiac and vascular organ failure by 72 hpf in bar mutant embryos.
Cardiovascular failure is related to altered redox signaling and an increased production of ROS (Hare and Stamler, 2005) . bar mutants compared to wild-type siblings show altered redox balance and oxidative stress features evaluated as an increase of the NADP/NADPH ratio and as an overexpression of antioxidant genes, respectively ( Figures 1E and 1F ). Increase of ROS production occurs specifically in cardiovascular tissues as demonstrated by measuring oxidizing species in ECs of bar mutants using the selective and stable ROS detector CellROX ( Figure 1G ). We also measured S-nitrosylation levels on heart and blood vessel sections of bar mutants. bar mutants show higher levels of S-nitrosylated proteins in heart and blood vessel cells as well as in pronephros as measured by an antibody against S-nitroso-cysteine (SNO-Cys) ( Figure 1H ). A high level of S-nitrosylated proteins is normally associated with altered redox signaling and cellular protection against oxidative stress (Stamler et al., 2001; Hess et al., 2005; Sun and Murphy, 2010) .
We found that cardiovascular tissues from bar mutants are positive for 8-hydroxy-2 0 -deoxyguanosine (8-OHdG), a free radical-induced oxidative lesion in DNA ( Figure 1I ). Analyses of heart and blood vessel sections show that both myocardial and endothelial tissues of bar mutants exhibit ROS-mediated DNA damage compared to controls. Indeed, endothelial and endocardial cells in bar mutants were positive for TUNEL staining and show typical morphological features of apoptotic cells at this stage ( Figure 1L ). In summary, both mutant embryos carrying the barolo mutation show increased oxidative stress, DNA damage, and cell death specifically in blood vessels and the heart.
We determined that bar encodes Ubiad1 (UbiA-domain containing protein 1) ( Figure 1M ). Sequence analyses show that the bar t31131 mutant allele contains a nonsense mutation (123 T > A) in ubiad1 introducing a premature stop codon at amino acid position 41, likely generating a null allele. The second allele of bar (bar s847 ) bears a base change (185 T > A) leading to the substitution of a conserved leucine residue to glutamine at amino acid position 62 (Ubiad1 L62Q ) ( Figure 1N ). bar s847 shows the same phenotypical features as bar t31131 except the phenotype is delayed by 12 hr (Figures S1A-S1E and S1T available online). Both bar allele mutants do not express Ubiad1 ( Figure 1O ) and are fully rescued by Ubiad1 mRNA expression. Ubiad1 L62Q mRNA does not rescue the bar t31131 mutant indicating that this amino acid mutation is sufficient to knock out Ubiad1 activity ( Figure 1P ). To confirm that Ubiad1 regulates cardiovascular protection and survival, we knocked down Ubiad1 expression using an antisense morpholino oligonucleotide. Ubiad1 morphants show the same hemorrhagic phenotype and cardiovascular defects as bar mutants (Figures S1F-S1I).
Analyses of ubiad1 mRNA expression in developing zebrafish embryos reveal a ubiquitous expression at 24 hpf in addition to a distinct expression in the heart at 48 hpf (Figures S1J-S1L), in agreement with mammalian expression data (Nakagawa et al., 2010) . In addition, cell transplantation and tissue-specific rescue experiments showed that Ubiad1 functions autonomously within endothelial and endocardial cells (Figures S1M-S1P and Table S1 ).
These data indicate that loss of ubiad1 triggers a progressive cardiovascular failure by increasing oxidative stress and apoptosis in heart and blood vessels suggesting a role for Ubiad1 as a controller of redox state and ROS levels in vertebrate cardiovascular tissues ( Figure S1Q ). Thereby, bar represents a unique model to study oxidative stress conditions and redox signaling during zebrafish development.
UBIAD1 Is a CoQ10 Biosynthetic Enzyme
Ubiad1 is conserved among species and contains an UbiA prenyltransferase domain, present also in the vertebrate protein Coq2. So far, the mitochondrial enzyme Coq2 is the only vertebrate enzyme known to synthesize CoQ10 through the prenylation of 4-hydroxybenzoic acid by oligoprenyl diphosphates (Forsgren et al., 2004) . The CoQ10 molecule is composed of a redox active benzoquinone ring, which is connected to a polyisoprenoid side chain of variable length (typically 9/10 units in vertebrates) (Crane, 2001) . As with Coq2, we speculate that Ubiad1 might catalyze the biosynthesis of CoQ10. We measured CoQ10 levels in bar mutants and ubiad1 morphants by HPLC-MS (Figures 2A and 2B ). The absence of Ubiad1 in zebrafish larvae significantly reduces CoQ10 levels ( Figure 2C ), whereas cholesterol levels are not significantly affected ( Figure S2A ). By the time course of synthesis analyses, we found that CoQ10 (legend continued on next page) increases during zebrafish embryonic development and is almost entirely produced by the zygote without any contribution from the yolk sac ( Figure S2B ). On the other hand, a significant amount of embryonic cholesterol is provided by the yolk sac throughout early development ( Figure S2C ). These data suggest that de novo zygotic synthesis of CoQ10 by Ubiad1 (and/or Coq2) is required for zebrafish development.
To test whether it is the absence of CoQ10 synthesis in zebrafish embryos that causes the bar phenotype, we injected CoQ10 in single-cell stage bar mutants ( Figure 2D ). Three different CoQ10 formulations rescue bar mutants, suggesting that the intake of CoQ10 in Ubiad1 deficient embryos may restore normal cardiovascular development. A recent paper reports that UBIAD1 is required for Vitamin K2 production (Nakagawa et al., 2010) ; however, our data indicate that a lack of Vitamin K2 is not responsible for the cardiovascular phenotype in bar mutants .
To provide biochemical evidence that Ubiad1 is able to synthesize CoQ10, we performed metabolic studies in zebrafish embryos by analyzing the ability of bar mutants to convert hydroxy-4-benzoic acid to CoQ10 ( Figure 2E ). We confirmed that administration of 13 C 6 -labeled hydroxy-4-benzoic acid (hydroxy-4-benzoic acid- 13 C 6 ) is metabolized to CoQ10- 13 C 6 in zebrafish embryos by injecting this C 13 -labeled precursor in zebrafish embryos at one-cell stage. After 72 hpf of incubation, lipids were extracted and analyzed by HPLC-MS to quantify the amount of CoQ10-13 C 6 formed ( Figure 2E ). bar mutants show a reduced CoQ10-13 C 6 production compared to wild-type siblings. CoQ9-13 C 6 production was also impaired ( Figure 2F ), indicating that zebrafish larvae can synthesize both CoQ9 and CoQ10 as can human cells (Turunen et al., 2004) . Therefore, Ubiad1 is a 4-OH-benzoic acid-prenyl-tranferase enzyme required for CoQ10 and CoQ9 biosynthesis in vivo.
Ubiad1 and HMG-CoA Reductase inhibitors act in the Mevalonate Pathway for CoQ10-Dependent Cardiovascular Oxidative Stress Protection.
The rate-limiting reaction in the biosynthesis of CoQ10 is the transfer of the polyprenyl-pyrophosphate (polyprenyl-PP) chain, derived from mevalonate, on to 4-OH-benzoic acid, derived from tyrosine metabolism (Bentinger et al., 2008) (Figure 2A) . We reduced the pool of polyprenyl-PP available for CoQ10 synthesis by treating zebrafish embryos with statins, inhibitors of its precursor (e.g., mevalonate) ( Figure S3A ). By blocking HMG-CoA reductase, statins impair the mevalonate and FPP synthesis, which is mandatory to synthetize the polyprenyl-PP chain (Figure 2A ). Wild-type embryos (ubiad1 +/+ ) treated with statin developed a bar-like phenotype ( Figures  3A-3C ). Statin treatments efficiently reduced CoQ10 synthesis without interfering with cholesterol levels, probably because statin treatment blocks de novo cholesterol biosynthesis but does not interfere with the maternally provided cholesterol (Figures 3D and 3E) . Zebrafish embryos treated with the squalene synthase inhibitor (SQI) or with farnesyl or geranyl-geranyl tranferase inhibitors (FTI or GGTI) did not exhibit a bar-like phenotype ( Figure S3B ), indicating that the absence of CoQ10 is the cause of the statin-induced cardiovascular oxidative phenotype. Furthermore, while treatment with a low-dose of statin did not produce any phenotype in wildtype (ubiad1 +/+ ) embryos, it caused a bar-like phenotype in embryos heterozygous for ubiad1 (ubiad1 +/À ) ( Figures 3F-3I ). The statin-dependent phenotype in embryos was efficiently rescued by exogenous administration of liposomal CoQ10 (Figures 3J and 3K and S3C) . To address the role of the mevalonate pathway in protection from oxidative stress in vivo, we measured ROS levels in zebrafish embryos treated with HMG-CoA reductase inhibitors. A ROS level increase is detected in statin-treated zebrafish embryos, and this oxidative stress was fully rescued by CoQ10 treatment ( Figure 3L ). These data suggest that HMG-CoA reductase and Ubiad1 are on the same metabolic pathway to produce CoQ10 as a potent antioxidant molecule which protects cardiovascular tissues during development. (P) Embryos from bar s847 and bar t31131 heterozygote intercrosses were injected with mRNA encoding for wild-type ubiad1 mRNA, ubiad1 L62Q or fluorescent protein cherry (ctrl). bar s847 as well as bar t31131 were not rescued by microinjection of ubiad1 L62Q mRNA. A, atrium; V, ventricle; DA, dorsal aorta; PCV, posterior cardinal vein; BuA bulbus arteriosus; PD, pronephric ducts; E, endocardium; M myocardium. All data are means ± SEM. **p < 0.01, ***p < 0.001. See also Figure S1 , Table S1 , and Movies S1, S2, S3, and S4.
UBIAD1 Synthesizes CoQ10 in the Golgi Compartment
To determine whether Ubiad1 could be an enzyme responsible for cellular CoQ10 production, we examined its subcellular localization. Ubiad1 is conserved among species and is predicted to be a transmembrane protein (Nickerson et al., 2010) . Using human primary ECs, we found that UBIAD1 localizes 13 C-based metabolomic approach used to demonstrate that Ubiad1 is a 4-OH-benzoic acid-prenyltranferase enzyme. Coenzyme Q10 (CoQ10) biosynthesis starts with formation of a hydroxy-benzoic acid head group (4-OH-benzoic acid) and a lipophilic polyisoprenoid tail (polyprenyl-PP). The aromatic precursor of the benzoquinone ring (4-OH-benzoic acid) derives from tyrosine. Synthesis of the polyisoprenoid tail takes place in the cytoplasm starting from acetyl-CoA through the mevalonate pathway (which is shared with the cholesterol and dolichol biosynthetic pathways). The polyisoprenoid tail is assembled by polyprenyl diphosphate synthase, which is responsible for determining the number of isoprene units (designated as n). Next is the condensation of the polyisoprenoid chain with the benzoquinone ring to form the 4-hydroxy-3-polyprenyl benzoic acid intermediate (PPHB) by a 4-OH-benzoicpolyprenyl-tranferase (UbiA-containing enzyme). The subsequent reactions (O-methylations and C-methylations, hydroxylations and decarboxylations) modify the structure of the aromatic ring, but some of the enzymes involved are still unknown. Exogenous 4-OH-benzoic acid-13 C 6 containing heavy carbon element ( 13 C) is administered to embryos and cells so that de novo synthesis of PPHB and therefore CoQ10 can be monitored by HPLC-MS analyses. Loss of UbiA-containing enzymes (red) blocks the condensation of the polyisoprenoid chain with the benzoquinone ring and then formation of CoQ-13 C 6 . 13 13 C 6 ) and 13 C 6 -labeled CoQ9 (CoQ9- 13 C 6 ) are detected by HPLC-MS in bar mutants and siblings at 72 hpf. Loss of Ubiad1 expression protein significantly reduces de novo CoQ10-13 C 6 synthesis by 78% (E) and de novo CoQ9-13 C 6 synthesis by 66.5% (F) . All data are means ± SEM. **p < 0.01, ***p < 0.001. See also Figure S2. in an asymmetric perinuclear region that resembles the Golgi compartment ( Figure S4A ). Colocalization studies using the Golgi-specific marker TGN46 demonstrate that endogenous UBIAD1 is in the proximity of the Golgi ( Figure 4A ). Also, green fluorescent protein (GFP)-tagged zebrafish Ubiad1 expressed in human ECs localizes in the same perinuclear region compartment and colocalizes with the Golgi markers, GM-130 and g-adaptin ( Figures 4B and4C) . Further, we observe a rapid redistribution of Ubiad1-GFP proteins in cells treated with brefeldin A, supporting its Golgi localization ( Figure 4D ).
We hypothesized that since UBIAD1 is localized in the Golgi compartment, this enzyme might be a nonmitochondrial CoQ10 prenyltransferase. To test this, we performed subcellular fractionation experiments on human ECs and detected UBIAD1 only in Golgi compartments and not in mitochondria ( Figure 4E ). We analyzed de novo CoQ10 synthesis in these subcellular fractions by incubating ECs with the hydroxy-4-benzoic acid- 13 C 6 precursor and observed a decrease in CoQ10-13 C 6 production in Golgi compartments compared to mitochondrial fractions when UBIAD1 expression is reduced ( Figure 4F ). These data indicate that UBIAD1 is a CoQ10 biosynthetic enzyme located in the Golgi membrane compartment where large amounts of cellular CoQ10 are normally synthesized (Kalé n et al., 1990; Swiezewska et al., 1993) .
SCCD Mutations Protect Cardiovascular Tissues from Oxidative Stress by CoQ10 Production
Mutations in the UBIAD1 gene are linked to the Schnyder Crystalline Corneal Syndrome (SCCD; OMIM 121800) (Weiss et al., 2007; Orr et al., 2007; Yellore et al., 2007) . Two common UBIAD1 mutations found in SCCD patients lead to N102S and D112G substitutions. We generated human UBIAD1 constructs carrying these mutations (UBIAD1-N102S and UBIAD1-D112G) and found that they were able to rescue the loss of Ubiad1 during zebrafish development. We tested these variants for levels of expression and CoQ10 synthesis in human ECs. Compared to wild-type UBIAD1 protein, SCCD variants were expressed at higher levels ( Figure 5B ). Furthermore, human ECs expressing the UBIAD-SCCD mutant proteins produced higher CoQ10 levels compared to wild-type protein (Figures 6C and 6D) . Intriguingly, SCCD mutations did not affect cholesterol synthesis in human ECs ( Figure 5E ). Although it remains unclear why SCCD mutation would results in the SCCD phenotype, these findings suggest that the SCCD variants are effective in CoQ10 production.
Ubiad1 and Coq2 Play Different Roles in CoQ10-Mediated Cardiovascular Oxidative Protection
CoQ10 is a mobile lipophilic electron carrier critical for electron transfer by the mitochondrial inner membrane respiratory chain (Mitchell, 1961; Turunen et al., 2004; Duncan et al., 2009) . Primary CoQ10 deficiencies have been associated with mutations in mitochondrial CoQ10 biosynthetic genes, such as COQ2 (Salviati et al., 2005; Quinzii et al., 2006) . In order to investigate whether the Golgi-localized Ubiad1 and the mitochondrial-localized Coq2 can have different functions in vivo, we knocked-down Coq2 expression during zebrafish develop-ment by morpholino (MO) injections. Similar to Drosophila sbo/ coq2 mutants , coq2 morphants are characterized by a general developmental delay, small body, and severe hindbrain edema ( Figures S5A-S5C) . These phenotypes do not occur in bar mutants or ubiad1 morphants, and, although a strong increase in oxidative stress occurs in coq2 morphants ( Figure 6B ), they did not show blood vessel regression (Figure 6A) . Therefore, loss of Coq2 leads to oxidative stress, but it does not significantly affect vascular integrity and survival. We measured CoQ9 and CoQ10 levels, and as expected, they dropped in coq2 and ubiad1 morphants, compared to controls, and in double morphants ( Figures 6C and S5D ). Loss of Ubiad1 and Coq2 in vivo unequivocally causes a decrease in CoQ10 levels that possibly increases oxidative damage in different subcellular compartments leading to different embryonic phenotypes.
To test whether Coq2 might compensate for loss of Ubiad1, we performed rescue experiments by injecting mRNA encoding for Coq2 in bar mutants ( Figure 6D ). Although coq2 mRNA injection could rescue coq2 morphants (data not shown) it did not rescue bar mutants, suggesting that Coq2 does not protect cardiovascular tissues from oxidative stress during zebrafish development. MitoQ is a mitochondria-targeted antioxidant (Murphy and Smith, 2007) . Due to its selective accumulation within mitochondria, MitoQ only protects against the mitochondrial oxidative damage that is caused in embryos and cells by blocking mitochondrial CoQ10 synthesis through knocking down Coq2 ( Figure S5E ). However, MitoQ (which will not interact with the Golgi apparatus) did not rescue bar mutants ( Figure 6D ), indicating that the two different subcellular pools of CoQ10 contribute in quite distinct ways to the phenotype.
To demonstrate the existence of a functional difference between the subcellular pools of CoQ10, we used human primary ECs where we can silence UBIAD1 and COQ2 genes at the same extent. Their silencing causes an increase in oxidative stress and accumulation of oxidative damage (Figure 6E) . To analyze the efficiency of UBIAD1 and COQ2 in total CoQ10 biosynthesis, we performed labeled precursor experiments where 4-hydroxybenzoic acid-13 C 6 was added to human ECs previously transfected with siRNA for UBIAD1 (siUBIAD1) or for COQ2 (siCOQ2) or both ( Figure S5F ). Silencing of UBIAD1 or COQ2 individually or together significantly reduced CoQ10-13 C 6 production. We also confirmed the efficiency of UBIAD1 and COQ2 siRNAs in decreasing endogenous total CoQ10 levels in ECs ( Figure 6F) . Interestingly, the silencing of the UBIAD1 gene did not significantly interfere with the transcriptional regulation of COQ2 and vice versa, indicating that the effect on CoQ10 levels from the silencing of one gene is not be altered by upregulation of the other ( Figure 6G ). We then analyzed mitochondrial morphology and viability in ECs that have been silenced for UBIAD1 or COQ2. The absence of COQ2 significantly altered mitochondrial morphology ( Figures  S5G and S5H ) and mitochondrial membrane potential (Figure 6H) , which can indeed be rescued by MitoQ ( Figure S5I ). Mitochondrial damage could not be detected in UBIAD1silenced cells, indicating that the lack of the mitochondrial pool of CoQ10 in COQ2-silenced cells exclusively impaired mitochondrial function. (G) images of Tg(kdrl:GFP) s843 ubiad1 +/+ and ubiad1 +/À embryos at 65 hpf treated with mevastatin (2.5 nM and 5 nM) from 32 to 50 hpf. Treatment with a low dose of statin caused hemorrhages (asterisks) and altered heart morphology (arrowheads) in ubiad1 +/À , but not in ubiad1 +/+ embryos. Although treatment with a low dose of statin did not induce specific alterations of the main vasculature, ubiad1 +/À embryos showed head vasculature, Se, and DA regression; scale bar, 300 mm.
(legend continued on next page) High levels of CoQ10 have been found in cellular membranes, including the Golgi and plasma membranes (Kalen et al., 1987; Turunen et al., 2004) . The presence of CoQ10 in nonmitochondrial membranes has been associated with its role in protecting membrane lipids from peroxidation as well as from an extracellular-induced ceramide-dependent apoptotic pathway (Navas et al., 2007) . We evaluated oxidative degradation of lipids by measuring lipid peroxidation in siUBIAD1-treated cells ( Figure 6I ). ECs without a cellular membrane pool of CoQ10 showed twice the level of oxidized fatty acid lipids, indicating a functional role for UBIAD1 in protection from oxidative species specifically localized in cellular but not mitochondrial membrane. We conclude that UBIAD1-derived CoQ10 prevents lipid peroxidation and propose a specific role for UBIAD1 in membrane protection from oxidative damage.
UBIAD1 Prevents a Shear Stress/Klf2a/eNOS-Mediated Oxidative Stress Pathway
A hemodynamic environment, such as shear stress, is known to lead to ROS generation, which is responsible for vascular remodeling and angiogenesis (Matlung et al., 2009 ). Kruppel-like factor 2 (Klf2) is an immediate mediator of hemodynamic forces created by blood flow and regulates flow-dependent blood vessel integrity both in zebrafish and mice (Lee et al., 2006; Nicoli et al., 2010) . By injecting cardiac troponin T2 (tnnt2) morpholino to block blood circulation (Sehnert et al., 2002) and klf2a morpholino (Nicoli et al., 2010) in bar mutants, we detected a significant delay of the bar phenotype as assessed by intersegmental vessels (Se) disintegration ( Figures S6A and S6B) . klf2a morpholino injection in barolo mutants lead to a partial recovery of oxidative stress in ECs ( Figure S6C ). These data indicate that a Klf2a-dependent shear stress pathway is required for oxidative stress conditions in bar mutants and that loss of Ubiad1 in vivo can be protected by impairment of this pathway.
In human endothelial cells KLF2 has been found to be directly responsible for eNOS expression and signaling (Searles, 2006) . Recently, a blood-flow-dependent klf2a-NO signaling cascade has been identified in developing zebrafish embryos (Wang et al., 2011) . Endothelial nos isoforms have been well characterized in zebrafish development (Fritsche et al., 2000; Pelster et al., 2005; North et al., 2009; Wang et al., 2011) . Inhibition of nos1 (the zebrafish ortholog of mammalian endothelial Nos) expression significantly rescued the bar mutant phenotype as well as endothelial regression (Figures 7A and 7B ). Since abrogation of nos1 expression may interfere with HSC development and blood flow we treated bar mutants at the onset of oxidative stress (32 hpf) with the selective inhibitor of eNOS activity, N-nitro-L-arginine methyl ester (L-NAME) (North et al., 2009 ). L-NAME treatment promoted a full morphological and functional cardiovascular recovery of a statistically significant number of bar mutants ( Figures 7C and 7D and S6E) . This recovery was carefully evaluated for ROS level and altered redox signaling (SNO-Cys staining) in ECs. Blocking of eNOS activity by L-NAME treatment significantly reduced oxidative stress in endothelial cells of bar embryos ( Figure 7E ) and restored normal redox signaling ( Figures 7F and S6E) . Pronephric duct cells affected by oxidative stress in bar mutants did not improve after L-NAME treatments ( Figure S6F ). We also evaluated the effect of the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) on bar mutants. SNAP treatments did aggravate the bar phenotype by increasing oxidative species in these mutant embryos (Figures S6D-S6F) . To test whether the source of ROS in the absence of UBIAD1 was caused by eNOS, we silenced eNOS in primary human ECs. ROS levels could be fully normalized by reducing eNOS expression in siUBIAD1-treated cells ( Figure 7G ).
To verify that the NO-forming activity of eNOS was compromised due to the lack of Ubiad1 and Golgi-CoQ10, we measured NOS activity in bar mutants and human ECs silenced for UBIAD1. The lack of Ubiad1 drastically reduced the formation of NO in zebrafish embryos ( Figure S6H ) as well as in human ECs ( Figure 7H ).
We measured tissue-specific NO levels in bar mutants by imaging DAF-2DA staining in live embryos. NO accumulation was reduced in the notochord (NC) and was completely absent in the bulbus arteriosus (BuA) of bar mutants compared with controls ( Figure S6I ). All together we show a specific role for Ubiad1 on regulation of eNOS-mediated NO formation in endothelial and cardiovascular cells in vivo.
These data indicate that the primary source of ROS causing cardiovascular oxidative stress in bar mutant as well as in ECs lacking UBIAD1 is dependent on eNOS activity. Therefore, we propose an unexpected functional link in the Golgi compartments between UBIAD1 and COQ10 in regulating eNOS activity and eventually NO signaling during cardiovascular development and homeostasis.
DISCUSSION

Ubiad1 Is a Prenyltranferase Enzyme Required for CoQ10 Biosynthesis in Golgi Membranes
CoQ10 is an important cellular and mitochondrial redox component and the only endogenously produced lipid-soluble antioxidant (Bentinger et al., 2010) . Although the genes encoding for the CoQ10 biosynthetic enzymes have been identified in (H) Images of Tg(kdrl:GFP) s843 ubiad1 +/+ and ubiad1 +/À embryos trunk vasculature show thinner and collapsed Se and DA morphology in statin-treated ubiad1 +/À but not in ubiad1 +/+ embryos. Scale bar, 75 mm. (I) Penetrance of bar-like phenotype at 65 hpf after treatment with mevastatin. ubiad1 +/À embryos are significantly more sensitive to develop a bar-like phenotype than normal embryos (ubiad1 +/+ ). (J) CoQ10 supplemented embryos show less susceptibility to statin treatments in terms of developing a bar-like phenotype as indicated by histograms showing the percentage of statin-treated embryos having bar-like phenotype after exogenous CoQ10 delivery. (K) CoQ10 supplementation before statin treatment prevents cardiac edema (arrowhead) and brain hemorrhages (asterisk) in barolo. Images of vehicle-and CoQ10-injected embryos after statin treatment. Scale bar, 300 mm. (L) Histograms show oxidative stress in embryos after statin treatment with or without CoQ10. All data are means ± SEM. ***p < 0.001. See also Figure S3 . bacteria and yeast, there is still only limited information about these synthetic enzymes in vertebrates (Turunen et al., 2004) . The rate-limiting enzyme for the biosynthesis of CoQ10 is the enzyme that catalyzes the condensation of the polyisoprenoid chain with the benzoquinone ring. So far, the mitochondrial COQ2 enzyme has been considered the only prenyltransferase able to catalyze this reaction (Trevisson et al., 2011) . Here, we identified UBIAD1 as a vertebrate CoQ10 prenyltransferase. UBIAD1 contains an UbiA prenyltransferase domain also present in vertebrate COQ2. Although COQ2 encodes a mitochondrial prenyltransferase, we found that UBIAD1 resides in the Golgi compartment where it produces CoQ10. While the presence of CoQ10 in nonmitochondrial membranes was previously explained by the existence of specific mechanisms for its redistribution within the cell (Crane and Morre, 1977; Jonassen and Clarke, 2000) , our data now formally demonstrate that CoQ10 are synthetized in the Golgi compartment.
In favor of our hypothesis of a Golgi-synthetized CoQ10, it has been recently reported that COQ6, COQ7, and COQ9, which are critical enzymes for CoQ10 maturation, are also localized in the Golgi compartment (Heeringa et al., 2011) . Similarly, these authors suggested that the Golgi-localized pool of CoQ10 may function in specific cells as an essential antioxidant for plasma membrane lipids that are normally derived from the Golgi compartment.
In this work, we demonstrated that the two distinct ubiquinone prenyltransferases act to resolve different molecular functions inside the cells and in living organisms. We found that COQ2mediated CoQ10 production is mainly for mitochondrial respiratory chain function and energy production, whereas UBIAD1mediated CoQ10 production is important for membrane redox signaling and protection from lipid peroxidation.
Ubiad1 and CoQ10: An Antioxidant System Controlling Redox Cellular Membrane in Cardiovascular Tissues
Oxidative damage is caused by an imbalance between the production of ROS and the antioxidant network. Although ROS are predominantly implicated in causing cell damage and premature aging via oxidation of DNA, lipids, and proteins, they also play a major physiological role in several aspects of intracellular signaling and regulation, especially in cardiovascular tissues (Hare and Stamler, 2005; Kuster et al., 2010) . Therefore, heart, endothelial, and vascular smooth-muscle cells need an efficient antioxidant network to balance ROS levels. We have shown a set of genetic and cellular data that reveal an unexpected role for UBIAD1 as an essential antioxidant gene with important functions in the protection of heart and endothelial cells from oxidative stress at the level of cellular membranes by producing CoQ10 in the Golgi for distribution to nonmitochondrial membranes throughout the cell. In addition to its crucial role in oxidative phosphorylation, CoQ10 plays another vital role in cellular function as an antioxidant molecule. The antioxidant nature of CoQ10 is derived from its function as an electron carrier: in this role, CoQ10 continually shuttles between oxidized and reduced forms. As it accepts electrons, it becomes reduced. As it gives up electrons, it becomes oxidized. In its reduced ubiquinol form, the CoQ10 molecule will quite easily give up one electron, and thus act as an antioxidant. In such a way, CoQ10 inhibits lipid peroxidation by acting as a chain breaking antioxidant. Moreover, CoQH 2 reduces the initial lipid peroxyl radical, with concomitant formation of ubisemiquinone and an alkyl peroxide. This quenching of the initiating peroxyl radicals thereby prevents the propagation of lipid peroxidation and protects not only lipids, but also proteins from oxidation. In addition, the reduced form of CoQ10 might also contribute to the stabilization of the plasma membrane, regenerating antioxidants such as a-tocopherol. A crucial role in all these processes is played by NAD(P)H-dependent reductase(s) acting at the plasma membrane to regenerate the reduced ubiquinol form of CoQ10, contributing to the maintainance of its antioxidant properties (Navas et al., 2007) . This finding also opens an interesting link among cellular redox-state and metabolic pathways such as the mevalonate pathway.
An Essential Function for Ubiad1/CoQ10 in Regulation of NO Signaling
We have demonstrated that UBIAD1 protects cardiovascular tissue from ROS-mediated oxidative stress by producing CoQ10 Figure 5 . SCCD UBIAD1 Variants Rescue barolo Mutants and Positively Regulate CoQ10 Synthesis (A) wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms (N102S; D112G) rescue bar mutants at a significant extent. (B) Western blot analysis of protein extracts from HUAEC transfected with plasmids encoding for wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms (N102S; D112G). (C-E) HUAEC were transfected with plasmids encoding for wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms (N102S; D112G) and total lipid extracts were quantitated for CoQ10-13 C 6 (C) and CoQ10 by HPLC-MS (D) and for cholesterol by HPLC-UV (E) . Expression of all UBIAD1 proteins rises levels of CoQ10 as well as de novo synthetized CoQ10-13 C but does not change cholesterol levels in human ECs. All data are means ± SEM. **p < 0.01, ***p < 0.001. located in Golgi and plasma membranes. Major enzymatic pathways responsible for the generation of ROS in cardiovascular tissues are mainly NADPH oxidases and eNOS (Browning et al., 2012) . By using drug inhibition and gene inactivation approaches, we identify eNOS dysfunction as the primary cause of ROS increase in bar mutant and UBIAD1-silenced human ECs. The NO synthetized by eNOS is an essential factor for cardiovascular development and homeostasis in vertebrates (Alp and Channon, 2004; Pelster et al., 2005; North et al., 2009; Wang et al., 2011) . It has been suggested that CoQ10 might have a positive role in modulating NO-related pathways by recoupling eNOS in endothelial cells (Stuehr et al., 2001; Chew and Watts, 2004; Tsai et al., 2012) . eNOS is a ''L-arginine, NADPH:oxygen oxidoreductases, NO-forming enzyme'' (EC 1.14.13.39 ) that couples reduction of molecular oxygen to L-arginine oxidation and generation of L-citrulline and NO. eNOS controls the flow of electrons donated by NADPH to flavins FAD and FMN in the reductase domain of one monomer through BH4 to the ferrous-dioxygen complex (Fe) in the oxygenase domain. When NADPH and BH4 cofactors are limiting, electron transfer becomes uncoupled from L-arginine oxidation, the ferrous-dioxygen complex dissociates, and superoxide ( , O 2 À ) is generated from the oxygenase domain (Schmidt and Alp, 2007) .
Our data indicate that barolo mutants lacking the Golgi pool of CoQ10 die due to the accumulation of oxidative damage in cardiovascular tissues caused by ROS produced by eNOS. We suggest a mechanism whereby UBIAD1 is required in the Golgi compartment to produce CoQ10 as an important cofactor for eNOS-mediated NO production ( Figure 7I ). This model could fit with the oxido-reductive properties of CoQ10 and eNOS: the electron flux inside eNOS that is mandatory to produce NO from L-arginine might require CoQ10, together with NADPH and BH4. Such function would not be very different from what CoQ10 does in the mitochondrial electron transport chain (ETC) coupling electron transfer between an electron donor (such as NADH) and an electron acceptor (such as O 2 ) with the transfer of H + ions across the mitochondrial inner membrane. In the Golgi membranes, the flow of electrons within eNOS transfers electrons from NADPH to the (legend continued on next page) flavins FAD and FMN, which have the capacity to reduce molecular oxygen. If the ETC is disturbed, such as in the absence of UBIAD1/CoQ10, the ferrous-dioxygen complex dissociates, and O À 2 is generated from the FMN oxygenase domain (Liu et al., 2002; Rigoulet et al., 2011) . In cardiovascular tissues, the CoQ10 produced by UBIAD1 in the Golgi compartment may be an important cofactor to maintain eNOS in a coupled conformation (e.g., required to produce physiological NO) and, eventually, quench leaking-uncoupled electrons. We speculate that when UBIAD1/CoQ10 in the Golgi compartment is absent or decreased (bar mutants and siUBIAD1-treated cells) eNOS switches to an ''uncoupled'' conformation, producing oxidative species instead of NO and causing cardiovascular oxidative damage ( Figure 7I ). Further experiments need to be done to assess this hypothesis as well as the possibility that other NOS (e.g., nNOS) could be affected by the lack of Ubiad1 in vivo.
In summary, our study places UBIAD1 in a pathway with important therapeutic implications for cardiovascular failure, such as the opportunity to decrease oxidative damage and counteract some of the side effects of statins. In addition, pharmacological or genetic stimulation of UBIAD1, as a CoQ10 biosynthetic enzyme, represents a promising therapeutic approach for antioxidant-related diseases such as aging and cancer.
EXPERIMENTAL PROCEDURES
Zebrafish Strains, Mapping, Genotyping Embryos and adult fishes were raised and maintained under standard laboratory conditions. bar s847 and bar t31131 mutants were generated by ENU mutagenesis as previously described (Jin et al., 2007) .
Oxidative Stress Analyses in Zebrafish Embryos and Cells
Oxidative damage was detected by immunofluorescence on agarose sections of zebrafish embryos with the following markers: anti-8-hydroxy-2 0 -deoxyguanosine (1:500, Abcam) and anti-S-nitroso-cysteine (1:250, Sigma).
ROS levels were quantitated in isolated human (HUAEC) and zebrafish (Tg(Kdrl:GFP) s843 ) endothelial cells with CellROX Deep Red Reagent (Invitrogen; 2.5 mM) and analyzed by FACS.
Generation of Human SCCD Mutation in UBIAD1
Constructs containing the SCCD mutation N102S and D112G were introduced in pCS2+ plasmids and used for expression in zebrafish embryos as well as human ECs.
NO Levels and NOS Activity in Zebrafish Embryos and Human ECs NOS activity was assayed using the NOS Activity Assay Kit (Cayman Chemicals). NO levels were detected using the DAF-2 DA (Calbiochem).
Cell Culture Experiments
Human primary EC were purchased from Lonza and cultured according to the manufacturer's protocols (Lonza). Cells were electroporated with siRNA (Dharmacon).
HPLC Analyses
Samples for HPLC-MS analysis were zebrafish embryos (n = 25) or human HUAEC (2 3 10 6 cells). CoQ10 and CoQ9 levels were detected by HPLC-MS or HPLC-UV (as indicated). Total cholesterol from zebrafish embryos was analyzed by HPLC-UV. 4-Hydroxy-benzoic acid-13 C 6 was stocked in Dulbecco's modified Eagle's medium (DMSO) and dissolved in cell culture medium (1 mM) or microinjected in zebrafish embryo at one cell stage (2 mM). ECs or embryos were extracted after 48 or 72 hr, respectively, after labeled precursor administration. Extracts were quantified by HPLC-MS as described.
Exogenous CoQ10 and Vitamin K Administration
All chemicals and solvents for liposomal CoQ10 and Vitamin K formulation were purchased from Sigma Aldrich and Avanti Polar Lipids. Liposomal SINAMIT was a gift from Dr. Franz Enzmann (MSE Pharmazeutika GmbHT), liposomal LiQsorb was from Tishcon Corp. MitoQ was synthetized as previously reported (Murphy and Smith, 2007) . All CoQ10 and vitamin K formulations were tested for toxicity and microinjected at specific concentrations into zebrafish embryos at one cell stage.
For detailed procedure of refer to Extended Experimental Procedures. 
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